CNTX - CIK 0001842952
The table below shows Context Therapeutics Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$26.39M | -$14.56M | -$21.05M | -$13.55M | -$8.80M | -$1.03M |
| Capital expenditure | $33.95K | $7.32K | $0.00 | $36.84K | $0.00 | - |
| Investing cash flow | -$2.03M | -$14.76M | $0.00 | -$536.84K | -$250.00K | $0.00 |
| Dividends paid | - | - | - | - | - |
Context Therapeutics Inc. reported operating cash flow of -$26.39M for fiscal year 2025. That is down 81.3% from -$14.56M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$1.03M (FY 2020) to -$26.39M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$15.27K | $109.29M | $0.00 | -$102.07K | $58.39M | $1.15M |